Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Igen, Roche deal

ROCZ will acquire IGEN for $1.3 billion in cash plus stock in a newly formed spinoff. As a result of the deal, ROCZ has secured

Read the full 256 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE